Actively Recruiting
Effect of Celery Seed on the Components of Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion
Led by University of Guadalajara · Updated on 2024-10-23
28
Participants Needed
1
Research Sites
132 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The Metabolic Syndrome (MS) is a cluster of cardiometabolic risk factors, which include abdominal obesity, hyperglycemia, dyslipidemia, and high blood pressure. MS is a global health problem, it represents a risk factor for the progression of cardiovascular disease, which constitute the main cause of mortality in the world and in Mexico. The current treatment involves lifestyle changes and pharmacological treatment for each of the components of MS, however, there is no single approved treatment to control all components. Celery seed (Apium graveolens L.) from the Apiaceae family contains the flavonoids apigenin and luteolin; essential oils such as d-limonene, selinene and phthalides such as 3-n-butylphthalide. Thanks to its bioactive components, celery seed has proven to be effective in treating individual MS disorders; however, most studies are in animal models and there are no clinical studies that evaluate its effectiveness on all components of the system. MS, insulin sensitivity and insulin secretion so it could appear as a new, safe and effective complementary therapy for the treatment of MS. The aim of this study is to evaluate the effect of celery seed on the components of metabolic syndrome, insulin sensitivity, and insulin secretion.
CONDITIONS
Official Title
Effect of Celery Seed on the Components of Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients of both sexes
- Age between 30 and 60 years
- Diagnosis of metabolic syndrome according to IDF criteria: waist circumference 280 cm for women or 90 cm for men, plus two or more of the following: fasting glucose 25 mg/dL, triglycerides 150 mg/dL, HDL-c <40 mg/dL for men or <50 mg/dL for women, blood pressure 130/85 mmHg
- Body Mass Index between 25 and 34.9 kg/m�b2
- Stable weight with less than 10% variation over the past 3 months
- No pharmacological treatment for metabolic syndrome, insulin sensitivity, or insulin secretion
- Willingness to accept and sign informed consent
You will not qualify if you...
- Pregnancy or breastfeeding
- Fasting glucose 26 126 mg/dL
- Total cholesterol 240 mg/dL
- Triglycerides 250 mg/dL
- Systolic blood pressure 26 140 mmHg
- Diastolic blood pressure 26 90 mmHg
- Use of drugs or supplements that affect study variables
- History of kidney, liver, or thyroid disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
INSTITUTO DE TERAPÉUTICA EXPERIMENTAL Y CLÍNICA. Centro Universitario de Ciencias de la Salud
Guadalajara, Jalisco, Mexico, 44340
Actively Recruiting
Research Team
K
Karina G Pérez Rubio, PhD
CONTACT
M
Marisol Cortez Navarrete, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here